United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $4.69, $0.82 better than the analyst estimate of $3.87. Revenue for the quarter came in at $446 million versus the consensus estimate of $426.43 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.